A Wittig-olefination–Claisen-rearrangement approach to the 3-methylquinoline-4-carbaldehyde synthesis

Mukund G. Kulkarni*, Mayur P. Desai, Deekshaputra R. Birhade, Yunus B. Shaikh, Ajit N. Dhatrak and Ramesh Gannimani

Full Research Paper

Address:
Department of Chemistry, University of Pune, Ganeshkhind, Pune 411007, India; Fax: +91 (020) 25691728

Email:
Mukund G. Kulkarni* - mgkulkarni@chem.unipune.ac.in

* Corresponding author

Keywords:
acetal; Claisen rearrangement; oxidative cleavage; ring-closure; Wittig olefination

Abstract
Efficient syntheses are described for the synthetically important 3-methylquinoline-4-carbaldehydes 6a–h from o-nitrobenzaldehydes 1a–h employing a Wittig-olefination–Claisen-rearrangement protocol. The Wittig reaction of o-nitrobenzaldehydes with crotlyloxymethylene triphenylphosphorane afforded crotly vinyl ethers 2a–h, which on heating under reflux in xylene underwent Claisen rearrangement to give 4-pentenals 3a–h. Protection of the aldehyde group of the 4-pentenals as acetals 4a–h and subsequent oxidative cleavage of the terminal olefin furnished nitroaldehydes 5a–h. Reductive cyclization of these nitroaldehydes yielded the required 3-methylquinoline-4-carbaldehydes 6a–h in excellent yields. Therefore, an efficient method was developed for the preparation of 3-methylquinoline-4-carbaldehydes from o-nitrobenzaldehydes in a simple five-step procedure.

Introduction
Quinoline aldehydes are important synthetic intermediates in the synthesis of heterocyclic compounds that are used in the manufacturing of dyes [1] and pharmaceuticals [2,3]. 3-Substituted and 2,3-di-substituted quinoline-4-carbaldehyde derivatives are used in the synthesis of immunosuppressant KF20444 [4] and 5-HT₃ receptor antagonists [5]. Quinoline mevalonolactones, prepared from 3-methylquinoline-4-carbaldehyde, act as inhibitors of HMG-CoA reductase [6]. 3-Substituted quinoline-4-carbaldehyde derivatives are used in the development of molecular probes for the identification of extra interaction sites in the midgorge and peripheral sites of butyrylcholinesterase (BuChE) [7]. These derivatives are also exploited in the synthesis of DNA binders [8], macrolides [9], antitumor agents [10] and for the treatment of viral and parasitic infections [11].
Though there are a number of quite efficient methods for the preparation of quinoline-4-carbaldehyde [12-24], only a few methods [6,9] are available for the preparation of 3-methylquinoline-4-carbaldehyde derivatives. In connection with the synthesis of camptothecin, we needed a general, high-yielding method for the synthesis of 3-methylquinoline-4-carbaldehyde. It was considered that a properly substituted 2-(2-nitrophenyl)pent-4-enal [25-27] could be a fitting intermediate for this purpose. Such an intermediate is easily accessible through the Wittig-olefination–Claisen-rearrangement protocol developed in our group [28,29].

Results and Discussion

Reaction of the o-nitrobenzaldehydes 1a–h with crotyloxymethylene triphenylphosphorane under optimized reaction conditions (Scheme 1) gave crotyl vinyl ethers in good yields (Table 1). The geometrical isomers of the crotyl vinyl ethers 2a–d were well separated on TLC, and it was possible to separate them by column chromatography. In the case of other crotyl vinyl ethers 2e–h, all attempts to separate these (E)- or (Z)-isomers were unsuccessful.

Claisen rearrangement on either (E)- or (Z)-isomers 2a–d also led to a diastereomeric mixture of 4-pentenals. However, these diastereomers remained inseparable. The crotyl vinyl ethers 2e–h, on heating under reflux in anhydrous xylene, underwent the Claisen rearrangement smoothly to give the diastereomeric mixture of the corresponding 4-pentenals 3e–h in good yields (Table 1).

Treatment of the 4-pentenals 3a–h with ethylene glycol furnished the corresponding acetals 4a–h in good yields (Table 1). From the NMR spectra of these acetals, it was clear that they were also a mixture of diastereomers, although they appeared to be homogeneous on TLC. All attempts to separate the diastereomers at this stage were also unsuccessful. Subjecting these acetals to oxidative cleavage in aq THF furnished the aldehydes 5a–h in good yields (Table 1). The

![Scheme 1](image)

**Table 1**: Synthesis of 3-methylquinoline-4-carbaldehydes.

| Aldehydes 1 | 2<sup>a</sup> | 3<sup>b</sup> | % Yields of 4<sup>b</sup> | 5<sup>b</sup> | 6 |
|------------|-----|-----|-----------------|-----|-----|
| MeO | MeO | 90 | (Z/E = 1:1.48) | 91 | (Z/E = 1:1.87) |
| Cl | MeO | 90 | (Z/E = 1:1.48) | 83 | (Z/E = 1:1.42) |
| Br | MeO | 91 | (Z/E = 1:1.42) | 91 | (Z/E = 1:1.42) |
| OMe | MeO | 92 | (Z/E = 1:1.42) | 90 | (Z/E = 1:1.42) |

*Note: Values in parentheses represent the dr ratio.*
Table 1: Synthesis of 3-methylquinoline-4-carbaldehydes. (continued)

|   |   |   |   |
|---|---|---|---|
| 1d | 93 | (Z/E = 1:1.93) | 88 | (dr = 1:1.63) | 92 | (dr = 1:1.66) | 91 | (dr = 1:1.41) |
| 1e | 91c | 85 | (dr = 1:1.16) | 91 | (dr = 1:2.63) | 90 | (dr = 1:6) |
| 1f | 90 | (only (E)-isomer) | 83 | (dr = 1:9.01) | 92 | (dr = 1:1) | 91 | (dr = 1:6.58) |
| 1g | 92 | (Z/E = 1:2.06) | 83 | (dr = 1:2.42) | 91 | (dr = 1:1.11) | 90 | (dr = 1:1.5) |
| 1h | 91 | (Z/E = 1:1.94) | 85 | (dr = 1:1.87) | 90 | (dr = 1:1.86) | 91 | (dr = 1:1.44) |

Notes:

- 2a–d are separable geometrical isomers, whereas 2e, 2g and 2h are mixtures of inseparable geometrical isomers. The Z/E ratio of the geometrical isomers of 2g–h was calculated from their NMR signals.
- 3a–h, 4a–h and 5a–h are mixtures of diastereomers, and the diastereomeric ratio (dr) was calculated from their NMR signals.
- The Z/E ratio of the geometrical isomers of 2e cannot be calculated from their NMR signals.
- Known compound [6, 9].

NMR of these aldehydes revealed them again to be a mixture of diastereomers, although they appeared to be homogeneous on TLC. Reductive cyclization of these nitroaldehydes furnished the required 3-methylquinoline-4-carbaldehydes 6a–h.

Conclusion

A new and efficient methodology for the construction of a 3-methylquinoline-4-carbaldehyde framework, with 50–55% overall yield, through a Wittig-olefination–Claisen-rearrangement protocol has been developed.

Experimental General

Silica gel (100–200 mesh) was used for column chromatography. IR spectra were recorded on a Perkin Elmer model 1600 series FTIR instrument. $^1$H and $^{13}$C NMR (ppm, TMS, internal standard) in CDCl$_3$ were recorded on a JEOL FX 90Q, Varian Mercury 300 MHz and 75 MHz, respectively. CHN analysis was performed on a Thermo FLASH EA model 1112 series. TLC was checked either under UV light and/or charring after dipping into anisaldehyde solution.

General procedure for the Wittig olefination

To a suspension of the o-nitrobenzaldehyde (20 mmol) and crotyloxymethylenetriphenylphosphonium chloride (24 mmol, 1.2 equiv) in dry THF (40 mL) at 0 °C was added t-BuOK (24 mmol, 1.2 equiv) in small portions. After 40–45 min (TLC, ethyl acetate/petroleum ether 1:9), THF was removed under vacuum. Water (25 mL) was added to the reaction mixture, and then the aqueous layer was extracted with ethyl acetate (3 × 15 mL), the combined organic layer was dried over sodium sulfate, and ethyl acetate was evaporated under vacuum. The crude product, i.e., crotyl vinyl ether, was purified by using silica-gel column chromatography (mobile phase 1–3% ethyl acetate in petroleum ether). Crotyl vinyl ethers (a–h) were obtained in 84–89% yield.

General procedure for the Claisen rearrangement

The crotyl vinyl ethers 2a–h (17 mmol) obtained from the Wittig reaction were dissolved in anhydrous xylene (35 mL) and the solution was heated under reflux for 5–7 h (TLC, ethyl acetate/petroleum ether 1:9). Then, the solvent was removed under reduced pressure. The crude aldehyde was purified by
using silica-gel column chromatography (mobile phase 2–5% ethyl acetate in pet. ether). 4-Pentenals 3a–h were obtained in 83–89% yield.

**General procedure for the protection of aldehyde**

Aldehydes 3a–h obtained from Claisen rearrangement (15 mmol) were dissolved in anhydrous toluene (25 mL). To this solution, a catalytic amount of p-TSA (1.5 mmol, 0.1 equiv) and ethylene glycol (45 mmol, 3 equiv) were added. The reaction mixture was heated under reflux for 3–4 h (TLC, ethyl acetate/petroleum ether 1:9). After removal of the solvent under reduced pressure, water (20 mL) was added to the reaction mixture, and then the aqueous layer was extracted with ethyl acetate (3 × 15 mL), the combined organic layer was dried over sodium sulfate, and then the aqueous layer was removed under reduced pressure. Water (25 mL) was added to the reaction mixture, and then the aqueous layer was extracted with ethyl acetate (3 × 15 mL), the combined organic layer was dried over sodium sulfate, and ethyl acetate was evaporated under vacuum. Finally, the product was purified by silica-gel column chromatography (mobile phase 1–3% ethyl acetate in petroleum ether). The products 4a–h were obtained in 89–93% yield.

**General procedure for the oxidative cleavage of alkenes**

Alkenes 4a–h (13.5 mmol), obtained as described above, were dissolved in aq. THF (30 mL, THF/H₂O 1:1). N-Methylmorpholine-N-oxide (NMO) (27 mmol, 2 equiv) and potassium osmate (0.027 mmol, 2 mol %) were added to this solution. The mixture was stirred at room temperature for 2–3 h until the starting compound disappeared (TLC, ethyl acetate/petroleum ether 1:9). THF was removed under reduced pressure. Water (20 mL) was added to the reaction mixture, and then the aqueous layer was extracted with ethyl acetate (3 × 10 mL), the combined organic layer was dried over sodium sulfate, and ethyl acetate was evaporated under vacuum. Finally, the crude product was obtained after removal of the solvent under reduced pressure. The product was purified by using silica-gel column chromatography (mobile phase 4–7% ethyl acetate in petroleum ether). The products 6a–h were obtained in 89–93% yield.

**General procedure for the reductive cyclization**

Aldehydes 5a–h (11 mmol) were dissolved in glacial acetic acid (20 mL) and heated under reflux with zinc dust (5 equiv) for 0.5 h (TLC, ethyl acetate/petroleum ether 1:9). Acetic acid was evaporated under vacuum, and chloroform was added to the residue. The solution was filtered through a celite bed. CHCl₃ was removed under reduced pressure. Water (25 mL) was added to the reaction mixture, and then the aqueous layer was extracted with ethyl acetate (3 × 15 mL), the combined organic layer was dried over sodium sulfate, and ethyl acetate was evaporated under vacuum. The crude product was obtained and purified by silica-gel column chromatography (mobile phase 2–3% ethyl acetate in petroleum ether). The products 6a–h were obtained in 84–87% yield.

**Supporting Information**

**Supporting Information File 1**

IR, ¹H NMR, ¹³C NMR and CHN analysis and spectral data of synthesized compounds.

The geometric isomeric ratios for 2g and 2h and diastereomeric ratios for 3a–h, 4a–h and 5a–h were calculated from their NMR signals.

[http://www.beilstein-journals.org/bjoc/content-supplementary/1860-5397-8-197-S1.pdf]

**Acknowledgements**

MPD would like to thank UGC, New Delhi and DRB, YBS, and RG would like to thank CSIR, New Delhi for the fellowship.

**References**

1. Gross, W.; Oberkobusch, D.; Höfkes, H.; Moch, M. Hair Colourants. W.O. Patent 2007/073923, July 5, 2007.
2. Allen, D. R.; Buckley, G. M.; Bürl, R.; Davenport, R. J.; Kinsella, N.; Lock, C. J.; Lowe, C.; Mack, S. R.; Pitt, W. R.; Ratcliffe, A. J.; Richard, M. D.; Savin, V. M.; Sharpe, A.; Tait, L. J.; Warrelow, G. J.; Williams, S. C. Quinoline and Quinoxline Derivatives as Kinase Inhibitors. W.O. Patent 2009/081105, July 2, 2009.
3. Schmitt, M.; Klotz, E.; Machere, J.-P.; Bourguignon, J.-J. Compositions Derived from Quinoline and Quinoxline, Preparation and Use Thereof. W.O. Patent 2003/010146, Feb 6, 2003.
4. Chuo, I.; Masuda, Y.; Fujino, K.; Kato, S.; Ogasahara, T.; Mohri, S.-i.; Kasai, M. Bioorg. Med. Chem. 2001, 9, 3273–3286. doi:10.1016/S0968-0896(01)00238-3
5. Cappelli, A.; Anzini, M.; Vornero, S.; Mennuni, L.; Markovec, F.; Doucet, E.; Hamon, M.; Menziani, M. C.; De Beneditti, P. G.; Giorgi, G.; Ghelardini, C.; Collina, S. Bioorg. Med. Chem. 2002, 10, 779–801. doi:10.1016/S0968-0896(01)00332-7
6. Sliskovic, D. R.; Picard, J. A.; Roark, W. H.; Roth, B. D.; Ferguson, E.; Krause, B. R.; Newton, R. S.; Sekerke, C.; Shaw, M. K. J. Med. Chem. 1991, 34, 367–373. doi:10.1021/jm00105a007
7. Campiani, G.; Faltonorusso, C.; Butini, S.; Gaeta, A.; Agnusdei, M.; Gemma, S.; Persico, M.; Catalano-ti, B.; Savini, L.; Nacci, V.; Novellino, E.; Holloway, H. W.; Greig, N. H.; Belinsky, T.; Fodor, J. M. Med. Chem. 2005, 48, 1919–1929. doi:10.1021/jm049510k
8. Lyakhova, E. A.; Lyakhov, S. A.; Litvinova, L. A.; Andronali, S. A.; Lebedyuk, M. N.; Fedchuk, V. P.; Khokhrokhina, G. A. Pharm. Chem. J. 2005, 39, 183–187. doi:10.1016/s1191-0045-00113-0
9. Chupak, L. S.; Flanagan, M. E.; Kaneko, T.; Magee, T. V.; Nee, M. C.; Reilly, U. Macrolides. U.S. Patent 2006/0135447, June 22, 2006.
10. Da Rocha Pitta, I.; Alves De Lima, M. d. C.; Lins Galdino, S.; Barbe, J. Molecules with Antitumor Activity and Chemical Synthesis. W.O. Patent 2004/024058, March 25, 2004.
11. Giannini, G.; Pisano, C.; Vesel, L.; Tinti, M. O.; Merlini, L.; Penco, S.; Zunino, F. 7- Polyaminoalkyl(oxy) Iminomethylcamptothecins Bearing Protective Groups. U.S. Patent 2007/0043067, Feb 22, 2007.
12. Pérez-Melero, C.; Maya, A. B. S.; del Rey, B.; Peláez, R.; Caballero, E.; Medarde, M. Bioorg. Med. Chem. Lett. 2004, 14, 3771–3774. doi:10.1016/j.bmcl.2004.04.098
13. Ramadas, S. R.; Krishna, M. V. Curr. Sci. 1981, 50, 120–123.
14. Kwartler, C. E.; Lindwall, H. G. J. Am. Chem. Soc. 1937, 59, 524–526. doi:10.1021/ja01282a027
15. MacDonald, S. F. J. Am. Chem. Soc. 1947, 69, 1219–1220. doi:10.1021/ja11197a111
16. Plöbeck, N.; Delorme, D.; Wei, Z.-Y.; Yang, H.; Zhou, F.; Schwarz, P.; Gasweit, L.; Gagnon, H.; Pelman, B.; Schmidt, R.; Yue, S. Y.; Walpole, G.; Brown, W.; Zhou, E.; Labarre, M.; Payza, K.; St-Onge, S.; Kamassah, A.; Morin, P.-E.; Projean, D.; Ducharme, J.; Roberts, E. J. Med. Chem. 2000, 43, 8378–8384. doi:10.1021/jm000228x
17. Achremowicz, L. Synth. Commun. 1996, 26, 1681–1684. doi:10.1080/00397919608002606
18. Nishikawa, T.; Ino, A.; Isobe, M.; Goto, T. Chem. Lett. 1991, 7, 1271–1274. doi:10.1246/cl.1991.1271
19. Mathes, W.; Sauermilch, W. Chem. Ber. 1954, 87, 1179–1183. doi:10.1002/cber.19540870820
20. Ihara, M.; Noguchi, K.; Fukumoto, K.; Kamatani, T. Tetrahedron 1985, 41, 2109–2114. doi:10.1016/S0040-4020(01)96581-0
21. Giordano, C.; Minisci, F.; Vismara, E.; Levi, S. J. Org. Chem. 1986, 51, 536–537. doi:10.1021/jo00354a026
22. Vismara, E.; Francesca, F.; Francesco, M. Gazz. Chim. Ital. 1987, 117, 135–136.
23. Kulkarni, M. G.; Davawala, S. I.; Dhonde, A. P.; Gaikwad, D. D.; Borhade, A. S.; Chavhan, S. W. Tetrahedron Lett. 2006, 47, 1003–1005. doi:10.1016/j.tetlet.2005.11.134
24. Kulkarni, M. G.; Chavhan, S. W.; Desai, M. P.; Shaiakh, Y. B.; Gaikwad, D. D.; Dhonde, A. P.; Borhade, A. S.; Ningdale, V. B.; Birhade, D. R.; Dhatrak, N. R. Tetrahedron Lett. 2010, 51, 4494–4496. doi:10.1016/j.tetlet.2010.06.068
25. Kulkarni, M. G.; Dhonde, A. P.; Chavhan, S. W.; Borhade, A. S.; Shaiakh, Y. B.; Birhade, D. R.; Desai, M. P.; Dhatrak, M. P. Beilstein J. Org. Chem. 2010, 6, 876–879. doi:10.3762/bjoc.6.103
26. Kulkarni, M. G.; Davawala, S. I.; Doke, A. K.; Pendharkar, D. S. Synthesis 2004, 17, 2919–2926. doi:10.1055/s-2004-831208

License and Terms

This is an Open Access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The license is subject to the Beilstein Journal of Organic Chemistry terms and conditions: (http://www.beilstein-journals.org/bjoc)

The definitive version of this article is the electronic one which can be found at: doi:10.3762/bjoc.8.197